Loading
Antiverse
Antiverse is a Cardiff techbio company. It combines machine learning, proprietary datasets, cell-line engineering and in-house labs in a lab-in-the-loop platform for de novo antibody design. It works with pharma partners, including several top-20 pharma companies and Nxera, and the Cystic Fibrosis Foundation. It also advances its own antibody programmes toward in vivo studies. In March 2026 it closed a $9.3M Series A led by Soulmates Ventures, bringing total funding to over $20M. It has offices in Boston and Prague.
Funding
Every round, secondary, debt facility or acquisition involving Antiverse that Lounge tracks, newest first.
No rounds recorded yet.
Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.
See plans →Log inKey numbers
—
0
—
—